In most of the cases, biochemical markers (e.g., ALT) and fibrotic markers (e.g., ferritin) as well as imaging techniques for the evaluation of hepatic fat content (MRI, CT, transient elastography (FibroScan), and ultrasonography) and the NAS were used in order to assess the effect of GLP-1 RAs in hepatic steatosis or fibrosis [105]. This evidence concerns the gene GLP1R and fatty liver disease.